ZTE
29.9.2014 04:49:13 CEST | Business Wire | Pressemeddelelse
ZTE, one of the global leaders in the mobile handset manufacturing industry, launches its three new smartphone devices at this year’s Gitex Shopper and has announced its strategic partnership with Global Distribution FZE, a leading distributor of IT and Mobility products as the exclusive distributor of ZTE-Smartphone products in the UAE.
Aiming to take on a bigger market share in the Middle East smartphone market, ZTE is showcasing its flagship products – Grand SII LTE, Nubia Z5S Mini and Blade Vec 4G – to the region for the first time. Deemed to be a ‘game changer’ in the region’s smartphone segment, the launch of these products is part of the global telecommunications company’s strategic efforts to strengthen its market presence in the Middle East.
“The UAE, one of the leaders in the global telecommunication industry with sophisticated growth in 4G network market, is one of our most concerned markets. In order to strengthen ZTE’s pioneer position in the GCC market, we see Dubai as an access to integrate into the wider Middle East & North Africa (MENA) region. We will launch premium products in this region through open channel and operator channel,” said Ning Tian, Regional Director of MENA, ZTE Mobile Device.
ZTE’s flagship revolutionary 4G smartphones launched at Gitex Shopper are innovative with top-of-the-line features. The Grand SII LTE , known for its exceptional processing speed, is one of the world’s fastest 4G smartphones. It is paired with the new Qualcomm Snapdragon 801 processor. It has a 5.5-inch full HD, 1080p display, providing a crystal clear display.
Running on Android 4.3 OS, the Grand SII LTE is packed with one unique security option that enables users to unlock their handset with their voices, using a phrase of their choice. It also has improved audio features for clearer calls and a 13-megapixel camera, a 2-megapixel front-facing camera for better quality photos.
The Nubia Z5S Mini appeals to customers’ needs for aesthetic value with its stylish look designed by an Italian artist Stefano Giovannoni. It is also packed with 4G chipset MSM8926 Quad core 1.2Ghz and is equipped with a 4.7-inch, 720p touch screen, one of Sharp’s excellent IGZO panels. It has 4G LTE connectivity and a MicroSD card slot to increase the 16GB of internal memory.
The Nubia Z5S Mini has 13 megapixels on the rear, and is equipped with a backside illuminated sensor with an F2.2 aperture, all hidden behind a sapphire lens, along with an LED flash and a 5-megapixel front camera. Offering a choice of three modes, including an auto and a pro mode for improved control, this ZTE smartphone will satisfy the needs of selfie and groufie lovers.
Meanwhile, featuring a quad-core Qualcomm processor and a crisp TFT 5-inch display, ZTE Blade Vec 4G is just 7.8mm thick. The back of the device is made of glass fibre with special stripes design, making it fashionably scratch-proof. This 4G smartphone has a 1280 x 720 display and an 8MP camera and runs on Android 4.4 KitKat.
“There has been a tremendous growth across the global smartphone industry particularly in Middle Eastern countries such as the UAE and Saudi Arabia. This region – expected to account for the second largest smartphone population in the world, according to International Data Corporation (IDC)’s Quarterly Mobile Phone Tracker – is definitely one of the primary target markets for ZTE and we are committed to establish our brand in the smartphone market by providing products that are suitable to consumers’ needs,” said Tian.
Tao Jiang, Vice President of EMEA (Europe, Middle East & Africa), ZTE Mobile Device added, “While ZTE is already prominent in many countries in terms of our terminal products that help build and sustain infrastructures, we are also optimistic that our new and innovative smartphones will also gain ground and attain a considerable share in the smartphone and mobile market in the coming years in UAE.”
ZTE aims to ship 60 million smartphones in 2014 and expects revenue from the terminal device unit to grow more than 15 percent in 2014 from a year earlier.
These three flagship products along with ZTE’s new line of smartphones will be displayed at their stand at Gitex Shopper, happening from 27th September to 4th October at Dubai World Trade Centre.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140928005086/en/
Contact:
ZTE Corporation
Eva Chen, +86 21 68897511
chen.zhengying@zte.com.cn
or
Waggener
Edstrom Communications
Laura Liu, +86 10 59001242
laural@waggeneredstrom.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum